Session 1095: Multidrug Resistance - MDR

Cochair(s): L Coussens, C Dittrich
Date: Sun 10 February 2002, Time: 14:00 - 15:30
Location: Amphithéâtre Duclaux

Oral Presentations

Time Number Title / Authors / Affiliations
14:00 447 Proteasome inhibition as a novel approach to cancer therapy
J Adams
Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts
14:15 448 The lambda-Int family recombinases, Cre and Flp are inhibited by topoisomerase I targeting anticancer drugs
RF Frøhlich, SG Hansen, FF Andersen, JR Olesen, M Jayaram, O Westergaard, BR Knudsen
1Department of Molecular and Structural Biology, University of Aarhus, Aarhus, Denmark, 2Section of Molecular Genetics and Microbiology, University of Texas, Austin, TX
14:30 449 Molecular basis of the ability of new antitumour agents - benzoperimidines and anthrapyridones - to overcome multidrug resistance.
J Tarasiuk, B Stefanska, K Tkaczyk-Gobis, A Garnier-Suillerot, E Borowski
1Department of Pharmaceutical Technology and Biochemistry, Technical University of Gdansk, Poland, France, 2Laboratoire de Physicochimie Biomoleculaire et Cellulaire, 3Universite Paris Nord, Paris, France, 4Department of Biochemistry, University of Szczecin, Poland
14:45 450 Genomic gain and loss associated with drug-resistance of CCRF-CEM leukemic cells
T Efferth, I Verdorfer, A Sauerbrey, H Miyachi, CR Chitambar, HG Drexler, E Gebhart
Virtual Campus Rhineland-Palatinate, Mainz, Germany
15:00 451 The cyclosporin PSC 833 prolongs survival of NOD-SCID mice following xenotransplantation with human myeloblasts carrying P-glycoprotein
G Lehne, D Sørensen, GE Tjønnfjord, C Beiske, HE Rugstad, T-A Hagve, OPF Clausen
1Department of Clinical Pharmacology, Department of Comparative Medicine, 2Department of Clinical Pharmacology, Department of Internal Medicine, 3Department of Clinical Pharmacology, Institute for Pathology, 4Department of Clinical Pharmacology, and Department of Clinical Chemistry, 5Department of Clinical Pharmacology; Rikshospitalet University Hospital, Oslo, Norway
15:15 452 DNA methyltransferase-3b is preferentially expressed in drug resistant cells
RS Dwivedi, Y-Y Qiu, BL Mirkin
Childrens Memorial Institute for Education and Research, Childrens Memorial Hospital and Department of Pediatrics, Northwestern University Medical School, Chicago, USA [ok]

Poster Presentations

Number Title / Authors / Affiliations
453 Evaluation of multidrug resistance in in vitro treated cells of cancerous patients versus healthy donors by single cell gel electrophoresis assay (SCGE) assay.
P Poli, A Buschini, C Alessandrini, A Martino, L Pasini, V Rizzoli, S Bonomini, C Rossi
1Istituto di Genetica, 2Cattedra di Ematologia; Università di Parma, Italy
454 The activity of latent benzoperimidine esters to inhibit P-glycoprotein and MRP1 dependent efflux of pirarubicin from several lines of multidrug resistant tumour cells.
D Glowacka-Rogacka, M Arciemiuk, A Kupiec, MM Bontemps-Gracz, E Borowski, J Tarasiuk
Department of Pharmaceutical Technology and Biochemistry, Department of Biochemistry, Technical University of Gdansk, Poland, Poland
455 The effect of new antitumor agents on the energy metabolism of human erythrocytes.
R Nowak, I Baranowska-Bosiacka, B Stefanska, J Hlynczak, J Tarasiuk
1 Department of Biochemistry, Poland 2 Department of Pharmaceutical Technology and Biochemistry, University of Szczecin, Technical University of Gdansk, Poland